Effects of AZD6765 and ketamine on brain responses.

• Research type

  Research Study

• Full title

  A Phase I, multi-centre, double-blind, placebo controlled parallel group study to assess the pharmacoMRI effects of ADZ6765 in male and female subjects fulfilling the criteria for Major Depressive Disorder

• Contact name

  J F W Deakin

• Contact email

  bill.deakin@manchester.ac.uk

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2009-013110-27

• Research summary

  The import did not bring in any data, please check the applicants form to see if they filled in the Research Summary. If so please import the form again. This problem may have been caused by the an application form being imported before the research summary functionality was available. Please phone the helpdesk if you have any questions or require advice.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  1029

• Date of REC Opinion

  23 Oct 2009

• REC opinion

  Favourable Opinion